AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15197377
Drug: Consultation and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consultation and training provided by nurse educators on best practice protocols for prevention of decline in activities of daily living, pain, and depression.
Trial: 11845946
Drug: Adapalene cream
RxNorm normalized name: Adapalene
DrugBank: Adapalene (DB00210)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adapalene cream 0.1%
Trial: 14700217
Drug: Tretinoin formulations
RxNorm normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tretinoin formulations (Avita cream 0.025%, Retin‐A cream 0.025%, Retin‐A cream 0.05%, Retin‐A Micro gel 0.1%, and generic cream 0.025%)
Trial: 7605761
Drug: Low-dose epinephrine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose epinephrine (EPI) intravenous infusion
Trial: 7605761
Drug: Phenylephrine (PHE)
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenylephrine (PHE) intravenous infusion
Trial: 2194537
Drug: Increased dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased dose of radiotherapy
Trial: 2194537
Drug: Addition of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Addition of endocrine treatment
Trial: 2194537
Drug: Addition of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Addition of cytostatic treatment
Trial: 85872
Drug: Pectin added
RxNorm normalized name: Pectin
DrugBank: Pectin (DB11158)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pectin added to glucose solution
Trial: 85872
Drug: Guar gum
RxNorm normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guar gum and pectin added to paracetamol
Trial: 11465516
Drug: Testosterone enanthate,
RxNorm normalized name: Testosterone Enanthate, enanthate 200 mg/mL intramuscular solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone enanthate, 200 mg, weekly intramuscular injections
Trial: 23788517
Drug: 320 mg
RxNorm normalized name: aspirin 320 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 320 mg Bacopa monnieri (BM)
Trial: 23788517
Drug: 640 mg
RxNorm normalized name: glycerin 1640 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 640 mg Bacopa monnieri (BM)
Trial: 19217460
Drug: Low-dose pravastatin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose pravastatin (10 mg/d)
Trial: 19217460
Drug: High-dose pravastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose pravastatin (40 mg/d)
Trial: 7868711
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg itraconazole daily
Trial: 15196159
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg itraconazole daily
Trial: 12068841
Drug: Sublingual apomorphine
RxNorm normalized name: apomorphine Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual apomorphine 2 mg
Trial: 12068841
Drug: Sublingual apomorphine
RxNorm normalized name: apomorphine Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual apomorphine 3 mg
Trial: 12068841
Drug: Sublingual apomorphine
RxNorm normalized name: apomorphine Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual apomorphine (general)
Trial: 12068841
Drug: Sublingual apomorphine
RxNorm normalized name: apomorphine Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual apomorphine
Trial: 9793702
Drug: Sumatriptan nasal
RxNorm normalized name: SUMAtriptan nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sumatriptan nasal spray (20 mg/dose)
Trial: 9793702
Drug: Subcutaneous injection
RxNorm normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of sumatriptan
Trial: 7620630
Drug: Laufband therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laufband therapy (LB) with body weight support (BWS) and assisted limb movements
Trial: 7620630
Drug: Laufband therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laufband therapy (LB)
Trial: 2515583
Drug: Recombinant interferon-Roferon
RxNorm normalized name: interferon gamma, porcine recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant interferon-Roferon (R-IFN) applied as ointment, 20,000 IU/g
Trial: 2515583
Drug: Human leukocyte
RxNorm normalized name: Human leukocyte antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human leukocyte interferon-Ginterferon (G-IFN) applied as ointment, 10,000 IU/g
Trial: 2515583
Drug: Both R-IFN
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both R-IFN and G-IFN
Trial: 31765640
Drug: Oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo plus education only
Trial: 31765640
Drug: Oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo plus biofeedback
Trial: 31765640
Drug: Responders to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Responders to fecal incontinence treatment
Trial: 30704287
Drug: Rivaroxaban 15
RxNorm normalized name: rivaroxaban 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 15 mg od plus a P2Y12 inhibitor (group 1)
Trial: 30704287
Drug: Rivaroxaban 2.5
RxNorm normalized name: rivaroxaban 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 2.5 mg bid plus dual antiplatelet therapy (group 2)
Trial: 30704287
Drug: Warfarin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin plus dual antiplatelet therapy (group 3)
Trial: 25565885
Drug: Pregabalin 300
RxNorm normalized name: pregabalin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin 300 mg/d
Trial: 24415567
Drug: Pregabalin 600
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pregabalin 600 mg/d
Trial: 27531675
Drug: Pregabalin flexible
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pregabalin flexible dose (150-600 mg/d)
Trial: 24399120
Drug: Prulifloxacin 600
RxNorm normalized name: Orbifloxacin
DrugBank: Orbifloxacin (DB11443)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prulifloxacin 600 mg for 15 days + Serenoa repens extract for 8 weeks
Trial: 24399120
Drug: Prulifloxacin 600
RxNorm normalized name: Orbifloxacin
DrugBank: Orbifloxacin (DB11443)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prulifloxacin 600 mg for 15 days
Trial: 21871782
Drug: Oral amoxicillin
RxNorm normalized name: amoxicillin Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral amoxicillin 500mg three times daily for 2 days, then oral amoxicillin for 3 more days
Trial: 21871782
Drug: Intravenous ampicillin
RxNorm normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ampicillin 1g four times daily for 2 days, then oral amoxicillin for 3 more days
Trial: 17599747
Drug: Corticosteroid treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid treatment (10 mg bipuvicaine, 40 mg triamcinolone hexacetonide)
Trial: 17599747
Drug: Placebo (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (10 mg bipuvicaine, 2 ml saline)
Trial: 11593094
Drug: Felodipine (with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine (with possible additional medications: ACE-inhibitor, beta-blocker, diuretic)
Trial: 8017036
Drug: Psychological Relaxation
RxNorm normalized name: Relax-DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychological Relaxation Therapy (PRT)
Trial: 8017036
Drug: No Psychological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No Psychological Relaxation Therapy (Control)
Trial: 2542629
Drug: Atenolol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (50 mg daily) with flunarizine (10 mg daily)
Trial: 30039986
Drug: Caffeine (CAF)
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine (CAF) 6 mg·kg-1
Trial: 28517955
Drug: Intensive medical
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive medical therapy (IMT) with prompt revascularization
Trial: 25376536
Drug: Dental floss
RxNorm normalized name: dental floss
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dental floss impregnated with 5% chlorhexidine gluconate, used twice a day for 15 days
Trial: 25376536
Drug: Waxed floss
RxNorm normalized name: Candelilla Wax
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waxed floss without impregnation, used twice a day for 15 days
Trial: 19454860
Drug: Multiple-dose LRPT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple-dose LRPT 40 mg/d for 12 days with coadministered single-dose warfarin 30 mg
Trial: 19454860
Drug: Single-dose warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose warfarin 30 mg alone
Trial: 17678656
Drug: CIMT (constraint‐induced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIMT (constraint‐induced movement therapy)
Trial: 18642635
Drug: Traditional intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional intervention (control treatment)
Trial: 15201103
Drug: Acupuncture combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture combined with ultrasound therapy
Trial: 12759515
Drug: Aspirin 100
RxNorm normalized name: aspirin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 100 mg/day plus acenocoumarol at a targeted INR of 2.4‐3.6
Trial: 12759515
Drug: Acenocoumarol alone
RxNorm normalized name: acenocoumarol
DrugBank: Acenocoumarol (DB01418)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acenocoumarol alone at the same dosage
Trial: 7907073
Drug: Interferon alfa
RxNorm normalized name: Interferon alfa
DrugBank: Interferon alfa (DB05258)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alfa (3 MU 3 times weekly for 6 months)
Trial: 7907073
Drug: Interferon alfa
RxNorm normalized name: Interferon alfa
DrugBank: Interferon alfa (DB05258)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alfa (12-month course: 3 MU 3 times weekly for the first 6 months, 2 MU for the following 3 months, and 1 MU for the last 3 months)
Trial: 2766862
Drug: High-dose cis-platinum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cis-platinum (120 mg/m2) combined with cyclophosphamide (600 mg/m2)
Trial: 2766862
Drug: Low-dose cis-platinum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose cis-platinum (60 mg/m2) combined with cyclophosphamide (600 mg/m2)
Trial: 19348
Drug: Gastropulgit Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastropulgit Gel (liquid antacid)
Trial: 22445501
Drug: Interleukin-1 receptor
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Interleukin-1 receptor antagonist (IL-1Ra)
Trial: 16182635
Drug: Interview-administered dietary
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interview-administered dietary recall (FIAS)
Trial: 10524635
Drug: Glycyrrhizin (group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycyrrhizin (group G)
Trial: 10524635
Drug: Glycyrrhizin plus
RxNorm normalized name: glycyrrhizinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycyrrhizin plus ursodeoxycholic acid (group G+U)
Trial: 7014277
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg oxatomide b.i.d.
Trial: 28681387
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (classical oral motor exercises)
Trial: 15226754
Drug: Iron supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron supplementation (15 mg iron and multivitamins)
Trial: 12553109
Drug: roxithromycin 300
RxNorm normalized name: roxithromycin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: roxithromycin 300 mg once daily for 28 days
Trial: 2465265
Drug: Inosine pranobex
RxNorm normalized name: inosine pranobex
DrugBank: Inosine pranobex (DB13156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inosine pranobex 3 g a day for four weeks
Trial: 31539674
Drug: Prolonged exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged exposure therapy (with or without virtual reality)
Trial: 28864749
Drug: Wuzhi tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wuzhi tablet co-administration with tacrolimus
Trial: 28864749
Drug: CYP3A5 genotype
RxNorm normalized name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8
DrugBank: Streptococcus pneumoniae type 8 capsular polysaccharide antigen (DB10326)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYP3A5 genotype plus Wuzhi tablet co-administration guided dosing
Trial: 28864749
Drug: Standard dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dosing of tacrolimus (control group)
Trial: 16322487
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg dextroamphetamine (AMPH) with physiotherapy
Trial: 16322487
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg dextroamphetamine (AMPH) with physiotherapy in moderate hemiparesis subgroup
Trial: 10539775
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of L-[1-(13)C]oxoproline and L-[3, 3-(2)H]cysteine
Trial: 10539775
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of L-[(15)N]oxoproline and L-[3,3-(2)H]cysteine
Trial: 8758790
Drug: Intraperitoneal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraperitoneal administration of DDP (100mg/m2)
Trial: 8758790
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of DDP (100mg/m2)
Trial: 1913123
Drug: Intravenous recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous recombinant tissue plasminogen activator (IV rt-PA)
Trial: 6749773
Drug: Atropine 0.13
RxNorm normalized name: ATROPINE 0.13/PHENOBARBITAL 15MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine 0.13 mg
Trial: 6363488
Drug: Atropine 0.26
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine 0.26 mg
Trial: 6749773
Drug: Higher doses
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher doses of atropine (exact dosage not specified)
Trial: 31440032
Drug: IDP‐73152 mesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDP‐73152 mesylate 40-320 mg
Trial: 31440032
Drug: IDP‐73152 mesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDP‐73152 mesylate 640 mg (fed state)
Trial: 26053170
Drug: SPD left‐side
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPD left‐side down (SPD‐L)
Trial: 23277897
Drug: High-dose influenza
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose influenza vaccine (60 mcg/strain)
Trial: 23277897
Drug: Standard-dose influenza
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose influenza vaccine (15 mcg/strain)
Trial: 19879995
Drug: LEISH-F1+MPL-SE vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEISH-F1+MPL-SE vaccine (10 microg recombinant Leishmania polyprotein LEISH-F1 antigen + 25 microg MPL-SE adjuvant)
Trial: 20688040
Drug: LEISH-F1+MPL-SE vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEISH-F1+MPL-SE vaccine
Trial: 16930788
Drug: Single subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single subcutaneous palmar injection blocks
Trial: 16930788
Drug: Palmar techniques
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palmar techniques (including single subcutaneous palmar block and transthecal block)
Trial: 9331018
Drug: Candesartan cilexetil
RxNorm normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Candesartan cilexetil (combined treatment)
Trial: 3120484
Drug: Intramuscular nicomorphine
RxNorm normalized name: nicomorphine
DrugBank: Nicomorphine (DB13454)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular nicomorphine post-operatively
Trial: 30206090
Drug: Mexiletine hydrochloride
RxNorm normalized name: Mexiletine Hydrochloride
DrugBank: Mexiletine (DB00379)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mexiletine hydrochloride (300 mg/day) administered orally three times a day for 4 weeks (period 1)
Trial: 30206090
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered orally three times a day for 4 weeks (period 1)
Trial: 24347765
Drug: melatonin (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: melatonin (6 mg)
Trial: 24347765
Drug: gabapentin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gabapentin (600 mg)
Trial: 18237297
Drug: Pre-injection anxiety
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein Injection [Arexvy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-injection anxiety levels
Trial: 11106143
Drug: Melatonin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (2 mg in a controlled-release formulation)
Trial: 9064946
Drug: Dobutamine (maximal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dobutamine (maximal dose: 9 micrograms/kg/min; n = 10)
Trial: 1370510
Drug: Immunotherapy (IT)
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy (IT) with alum-precipitated aqueous ragweed extracts
Trial: 6383654
Drug: Intravenous streptokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous streptokinase (average dose 845,000 U iv, administered at 2.8 ± 1.0 hr after onset of pain)
Trial: 6383654
Drug: Intracoronary streptokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary streptokinase (average dose 212,000 U ic, administered at 4.3 ± 1.4 hr after onset of pain)
Trial: 6383654
Drug: Historical control
RxNorm normalized name: typhus, historical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Historical control group (not specified dosage or timing)
Trial: 30261892
Drug: Soluble keratin
RxNorm normalized name: gold keratinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soluble keratin (KER) 0.8 g/kg bodyweight/day
Trial: 26817502
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (30 mg Zn/d)
Trial: 26817502
Drug: Placebo (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (5 mg Zn/d)
Trial: 24472253
Drug: 8 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8 weeks of preschool-based social communication treatment in addition to standard preschool program
Trial: 23257132
Drug: Qianggu Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qianggu Capsule and two disease-modifying antirheumatic drugs
Trial: 23257132
Drug: Two common-used
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two common-used antirheumatic drugs
Trial: 20698724
Drug: 1.3 g
RxNorm normalized name: glycerin 1.3 g RECTAL SUPPOSITORY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.3 g tranexamic acid
Trial: 20698724
Drug: 3.9 g
RxNorm normalized name: aspirin 3.9 GM Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.9 g tranexamic acid
Trial: 20698724
Drug: 0.4 g
RxNorm normalized name: psyllium 0.4 GM Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 g moxifloxacin (positive control)
Trial: 15458612
Drug: Hypericum extract
RxNorm normalized name: Hypericum extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypericum extract (HE) 900 mg/d
Trial: 7594327
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg and clarithromycin 400 mg (group 1, n = 22)
Trial: 7594327
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg and clarithromycin 800 mg (group 2, n = 12)
Trial: 7594327
Drug: Lansoprazole 60
RxNorm normalized name: dexlansoprazole 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 60 mg and clarithromycin 800 mg (group 3, n = 29)
Trial: 7594327
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg (n = 23)
Trial: 7594327
Drug: Lansoprazole 60
RxNorm normalized name: dexlansoprazole 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 60 mg (n = 13)
Trial: 7594327
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg (n = 15)
Trial: 160348
Drug: Sulindac 100
RxNorm normalized name: sulindac 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulindac 100 mg twice daily
Trial: 22480093
Drug: Ibuprofen 400
RxNorm normalized name: ibuprofen 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 400 mg thrice daily
Trial: 160348
Drug: Soluble aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soluble aspirin 600 mg thrice daily